Sakai H, Yogi Y, Minami Y, Yushita Y, Kanetake H, Saito Y
Department of Urology, Nagasaki University School of Medicine, Japan.
J Urol. 1993 May;149(5):1020-3. doi: 10.1016/s0022-5347(17)36285-7.
To determine whether the prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) immunoreactivities in prostatic carcinoma are reliable prognostic factors, the PSA and PAP immunohistochemical distribution was examined in needle biopsy specimens of 80 patients with advanced prostatic carcinoma. Our results indicated a higher cancer-specific survival rate in patients with a greater PSA or PAP immunostaining. Furthermore, a multivariate analysis of possible prognostic factors, that is patient age, clinical stage, Gleason score, serum PAP, PSA and PAP immunostaining scores, and the initial treatment, has confirmed that the difference in PAP immunoreactivity is the most important prognostic factor (p < 0.01) for advanced prostatic carcinoma, with the Gleason score (p = 0.06), clinical stage (p = 0.09) and PSA immunoreactivity (p = 0.48) being the second, third and fifth prognostic factors, respectively.
为了确定前列腺癌中前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）免疫反应性是否为可靠的预后因素，我们对80例晚期前列腺癌患者的穿刺活检标本进行了PSA和PAP免疫组化分布检测。我们的结果表明，PSA或PAP免疫染色较强的患者癌症特异性生存率更高。此外，对可能的预后因素进行多变量分析，即患者年龄、临床分期、Gleason评分、血清PAP、PSA和PAP免疫染色评分以及初始治疗，证实PAP免疫反应性差异是晚期前列腺癌最重要的预后因素（p < 0.01），Gleason评分（p = 0.06）、临床分期（p = 0.09）和PSA免疫反应性（p = 0.48）分别为第二、第三和第五预后因素。
